Literature DB >> 23271768

Temporal changes in the clinical approach to diagnosing prostate cancer.

William M Hilton1, Susan S Padalecki, Donna P Ankerst, Robin J Leach, Ian M Thompson.   

Abstract

The diagnosis and detection of prostate cancer has undergone profound changes over the past three decades, due primarily to the development and widespread clinical use of prostate-specific antigen (PSA) testing. These changes have led to substantial differences in the prostate cancer phenotype. It is important to understand these changes to develop appropriate treatment options for contemporarily diagnosed prostate cancer. We explored a group of four temporal changes in prostate cancer detection that occurred after the advent of PSA testing. Through changes in the use of PSA testing, performance of prostate biopsy, application of PSA testing in different age groups, and pathologic tumor grading, a significant increase in detection of potentially inconsequential prostate cancers has occurred. The prostate cancer of 2011 is generally a smaller, lower-grade tumor and more often observed in younger men. These changes in detection will allow for increased use of active surveillance for prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271768      PMCID: PMC3540883          DOI: 10.1093/jncimonographs/lgs038

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  48 in total

1.  Transperineal 12-core systematic biopsy in the detection of prostate cancer.

Authors:  M Kojima; T Hayakawa; T Saito; H Mitsuya; Y Hayase
Journal:  Int J Urol       Date:  2001-06       Impact factor: 3.369

2.  Prostate biopsy: how many cores are enough?

Authors:  Joseph C Presti
Journal:  Urol Oncol       Date:  2003 Mar-Apr       Impact factor: 3.498

3.  Transrectal biopsy to detect prostatic carcinoma: a review and report of 203 cases.

Authors:  J L EMMETT; R J BARBER KW Jr JACKMAN
Journal:  J Urol       Date:  1962-03       Impact factor: 7.450

4.  Prostate cancer and the Will Rogers phenomenon.

Authors:  Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

5.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

6.  The use of transrectal ultrasound in the diagnosis, guided biopsy, staging and screening of prostate cancer.

Authors:  F Lee; P J Littrup; G H Kumasaka; G S Borlaza; R D McLeary
Journal:  Radiographics       Date:  1987-07       Impact factor: 5.333

7.  Impact of age at diagnosis on prostate cancer treatment and survival.

Authors:  Seth K Bechis; Peter R Carroll; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

8.  Ultrasound-guided prostate biopsy. Biopty gun superior to aspiration.

Authors:  H Ragde; H C Aldape; C M Bagley
Journal:  Urology       Date:  1988-12       Impact factor: 2.649

Review 9.  Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen.

Authors:  R A Stephenson; J L Stanford
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  2 in total

1.  Epidemiological evidences on overdiagnosis of prostate and kidney cancers in Korean.

Authors:  Jong-Myon Bae
Journal:  Epidemiol Health       Date:  2015-03-07

2.  Human papillomavirus 16 infection as a potential risk factor for prostate cancer: an adaptive meta-analysis.

Authors:  Jong-Myon Bae
Journal:  Epidemiol Health       Date:  2015-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.